Finance

Lists
Outlook: 68.4% bullish·0.0% bearish
Go to analysis
XENE:NASDAQ
Xenon Pharmaceuticals Inc
$41.29
-1.92%
(-0.81) 1D
Nov 12, 2:55:23 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XENE...
Open
$42.05
High
$42.20
Low
$40.62
Mkt. cap
4.06B
Avg. vol.
1.53M
Volume
606.70K
52-wk high
$72.66
52-wk low
$33.38
EPS
-$4.70
Beta
0.11
Shares outstanding
98.28M
No. of employees
364
Open
$42.05
High
$42.20
Low
$40.62
Mkt. cap
4.06B
Avg. vol.
1.53M
Volume
606.70K
52-wk high
$72.66
52-wk low
$33.38
EPS
-$4.70
Beta
0.11
Shares outstanding
98.28M
No. of employees
364
News stories
From web sources and news partners
About Xenon Pharmaceuticals Inc
CEO-
Employees364
Founded1996
HeadquartersVancouver, British Columbia, Canada
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 16 analysts giving stock ratings to XENE in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for XENE in the last 3 months.
Highest
Current $41.29
$90.00 (+117.97%)
Average
$69.58 (+68.52%)
Lowest
$46.00 (+11.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Benjamin Burnett
Wells Fargo
Buy
Maintained
$64.00
+55%
11/11/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$80.00
+93.8%
11/10/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
11/09/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$70.00
+69.5%
11/09/2026
Serge Belanger
Needham
Buy
Maintained
$60.00
+45.3%
11/10/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$74.00
+79.2%
11/10/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$77.00
+86.5%
11/09/2026
Delma Caiati
Guggenheim
Buy
Reiterated
$73.00
+76.8%
10/29/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$73.00
+76.8%
10/29/2026
David Martin PhD
Bloom Burton
Buy
Maintained
$71.00
+72%
09/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
-
-
09/18/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$75.00
+81.6%
09/17/2026
Laura Chico
Wedbush
Buy
Maintained
$55.00
+33.2%
09/18/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/18/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$90.00
+118%
09/18/2026
David Hoang
Deutsche Bank
Hold
Downgraded
$46.00
+11.4%
09/18/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/18/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$90.00
+118%
08/06/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$63.00
+52.6%
06/22/2026
Andrew Tsai
Jefferies
Buy
Reiterated
$100.00
+142.2%
03/09/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$55.00
+33.2%
02/26/2026
Rudy Li
Wolfe Research
Buy
Initiated
$60.00
+45.3%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
87.70M
88.51M
99.22M
-
Cost of revenue
87.70M
88.51M
99.22M
-
Research and development expenses
-
-
-
95.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.07M
23.82M
23.93M
24.42M
Operating expense
22.07M
23.82M
23.93M
120.07M
Total operating expenses
109.77M
112.33M
123.16M
120.07M
Operating income
-109.77M
-112.33M
-123.16M
-120.07M
Other non operating income
-
-
-
-
EBT including unusual items
-104.72M
-104.87M
-111.32M
-108.59M
EBT excluding unusual items
-104.72M
-104.87M
-111.32M
-108.59M
Income tax expense
538.00K
-2.57M
-585.00K
1.84M
Effective tax rate
-0.51%
2.45%
0.53%
-1.70%
Other operating expenses
-
-
-
-
Net income
-105.26M
-102.30M
-110.74M
-110.44M
Net profit margin
-
-
-
-
Earnings per share
-1.31
-1.17
-1.11
-1.11
Interest and investment income
5.34M
6.91M
12.14M
11.62M
Interest expense
-
-
-
-
Net interest expenses
5.34M
6.91M
12.14M
11.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-109.16M
-111.74M
-122.60M
-119.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps